Orgenesis Inc. ROIC

ROIC of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROIC growth rates and interactive chart. Return on invested capital (ROIC) is a calculation used to assess a company's efficiency at allocating the capital under its control to profitable investments. Calculated as Net Operating Profit After Tax or EBIT*(1-tax rate) divided by average invested capital. Invested capital is calculated as equity plus long-term and short-term debt minus cash and short-term investments. ROIC is often compared to the Weighted average cost of capital (WACC). If it's above it, it is said the company is creating value, if it's below it's destroying it. A company with after tax operating profit of $10 million and invested capital of $50 million will have a ROIC of 20%.


Highlights and Quick Summary

  • Annual ROIC for 2020 was -300.55% (a 308.47% increase from previous year)
  • Annual ROIC for 2019 was -73.58% (a 8.93% increase from previous year)
  • Annual ROIC for 2018 was -67.55% (a 17.44% increase from previous year)
  • Twelve month ROIC ending September 29, 2021 was -96.77% (a -15.6% decrease compared to previous quarter)
  • Twelve month trailing ROIC decreased by -67.8% year-over-year
Trailing ROIC for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-96.77% -114.66% -221.62% -300.55%
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROIC of Orgenesis Inc.

Most recent ROICof ORGS including historical data for past 10 years.

Interactive Chart of ROIC of Orgenesis Inc.

Orgenesis Inc. ROIC for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -300.55%
2019 -73.58%
2018 -67.55%
2017 0.0%
2016 0.0%
2015 0.0%
2014 0.0%
2013 0.0%
2012 0.0%
2011 0.0%

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.